9LBA A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study
A. Inoue, T. Nukiwa(Tohoku University), Satoshi Oizumi(Hokkaido University), Yasuo Saijo(Ho Chi Minh City International University), Kenichi Kobayashi(Shiga University of Medical Science), Shunichi Sugawara(Sendai Kousei Hospital), K. Hagiwara, Makoto Maemondo(Miyagi Prefectural Hospital Organization), S. Morita(Tohoku University), Akihiko Genma
Cited by 15
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695